<p>礼来公司（NYSE:LLY - 获取免费报告）的股票在周四上涨了 1%。该股最高交易价格为$787.00，最后交易价格为$779.77。在交易过程中，共交易了 538,739 股，较平均交易量 3,211,798 股下降了 83%。该股此前收盘价为$772.00。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>辉瑞：购买该股票的四个理由</li>
</ul>
<p>几家研究公司最近对 LLY 进行了评估。美国银行在 12 月 10 日的研究报告中重申了对礼来公司的 “买入” 评级，并给出了$997.00 的目标价格。Truist Financial 在 10 月 10 日的报告中将礼来公司的目标价格从$1,000.00 上调至$1,033.00，并给予该公司 “买入” 评级。巴克莱在 10 月 31 日的研究报告中将礼来公司的目标价格从$1,025.00 下调至$975.00，并对该公司设定了 “增持” 评级。摩根大通在 9 月 13 日的报告中将礼来公司的目标价格从$1,050.00 上调至$1,100.00，并给予该股票 “增持” 评级。最后，Redburn Atlantic 在 11 月 4 日的研究报告中将礼来公司升级为 “持有” 评级。四位投资分析师对该股票给予了持有评级，十八位分析师则给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为$1,002.22。</p>
<p><strong>查看我们最新的 LLY 股票报告</strong></p>
<h2>礼来公司股票上涨 0.2%</h2>
<ul>
<li>三只大牌股票刚刚宣布了大幅分红增加</li>
</ul>
<p>该股市值为 7341.6 亿美元，市盈率为 83.61，市盈增长比率为 2.99，贝塔值为 0.41。该公司的 50 日移动平均价格为$798.30，200 日移动平均价格为$865.06。公司的债务与股本比率为 2.03，流动比率为 1.27，速动比率为 0.97。</p>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日发布了季度财报。该公司报告每股收益为$1.18，低于分析师一致预期的$1.52，差额为 ($0.34)。该公司季度收入为 114.4 亿美元，而分析师预期为 120.9 亿美元。礼来公司的股本回报率为 71.08%，净利润率为 20.48%。该公司的季度收入较去年同期增长了 20.4%。去年同期，该公司每股收益为$0.10。卖方分析师预测，礼来公司在当前财政年度的每股收益将达到$13.18。</p>
<h2>礼来公司增加分红</h2>
<ul>
<li>诺和诺德：GLP-1 销售的新动力即将到来</li>
</ul>
<p>该公司最近还披露了季度分红，将于 3 月 10 日支付。2 月 14 日的股东将获得每股$1.50 的分红。这比礼来公司之前的季度分红$1.30 有所增加。除息日为 2 月 14 日。这代表着每年$6.00 的分红和 0.78% 的收益率。礼来公司的分红支付比率目前为 64.86%。</p>
<p>礼来公司宣布其董事会已于 12 月 9 日启动了一项股票回购计划，允许公司回购 150 亿美元的股票。该回购授权允许公司通过公开市场购买最多 2% 的股票。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
<h2>礼来公司的内部交易</h2>
<p>在其他礼来公司的新闻中，首席会计官 Donald A. Zakrowski 在 11 月 8 日的交易中出售了 900 股礼来公司的股票。该股票以平均价格$803.38 出售，总交易额为$723,042.00。交易完成后，首席会计官现在持有该公司 5,480 股股票，价值约$4,402,522.40。此次交易使其持股减少了 14.11%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站访问。目前，内部人士持有该股票的 0.13%。</p>
<h2>机构资金流入和流出</h2>
<p>最近，一些大型投资者调整了他们在礼来公司的持股。国际资产投资管理公司在第三季度将其在礼来公司的股份增加了 87,091.7%。国际资产投资管理公司现在拥有 12,463,182 股该公司的股票，价值 11,041,631,000 美元，此前在上个季度又增持了 12,448,888 股。Pathway Financial Advisers LLC 在第三季度将其在礼来公司的股份增加了 92,759.9%。Pathway Financial Advisers LLC 现在拥有 1,022,388 股该公司的股票，价值 905,774,000 美元，此前在上个季度又增持了 1,021,287 股。Wulff Hansen &amp; CO.在第二季度将其在礼来公司的股份增加了 90,438.0%。Wulff Hansen &amp; CO.现在拥有 937,068 股该公司的股票，价值 848,403,000 美元，此前在上个季度又增持了 936,033 股。Integrated Investment Consultants LLC 在第三季度将其在礼来公司的股份增加了 37,140.7%。Integrated Investment Consultants LLC 现在拥有 694,167 股该公司的股票，价值 614,990,000 美元，此前在上个季度又增持了 692,303 股。最后，Comerica Bank 在第二季度将其在礼来公司的持股增加了 71.6%。Comerica Bank 现在拥有 1,512,983 股该公司的股票，价值 1,369,825,000 美元，此前在上个季度又增持了 631,312 股。机构投资者持有该公司 82.53% 的股份。</p>
<h2>礼来公司公司简介</h2>
<p>(获取免费报告)</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比礼来公司更好的股票</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>3 家传统科技公司重新崛起为 AI 领导者</li>
<li>什么是支撑位？</li>
<li>分析师最喜欢的网络安全股票：3 个顶级推荐</li>
<li>3 只提供优厚股息收益的天然气股票</li>
<li>分析师看好：3 家科技巨头的目标价被上调</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<p>→ 我们在 2021 年推荐了 Palantir，现在我们推荐这个...（来自 Behind the Markets）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTExNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTExNQ"/></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

礼来

<p>礼来公司（NYSE: LLY）股价上涨 1%，至 779.77 美元，交易量显著低于平均水平。分析师对其前景持积极态度，普遍评级为 “适度买入”，平均目标价为 1,002.22 美元。该公司报告季度每股收益为 1.18 美元，未达到预期，但收入同比增长 20.4%。礼来宣布每股股息增加至 1.50 美元，并启动 150 亿美元的股票回购计划，显示出对其股票价值的信心。近期的内部交易和机构投资反映出对该公司的持续关注</p>

<p>Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) shot up 1% on Thursday . The stock traded as high as $787.00 and last traded at $779.77. 538,739 shares were traded during trading, a decline of 83% from the average session volume of 3,211,798 shares. The stock had previously closed at $772.00.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）的股票在周四上涨了 1%。该股最高交易价格为$787.00，最后交易价格为$779.77。在交易过程中，共交易了 538,739 股，较平均交易量 3,211,798 股下降了 83%。该股此前收盘价为$772.00。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Pfizer: 4 Reasons to Buy This Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞：购买该股票的四个理由</li>
</ul>
</div><p>Several research firms recently weighed in on LLY. Bank of America reaffirmed a &#34;buy&#34; rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, October 10th. Barclays dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an &#34;overweight&#34; rating for the company in a research note on Thursday, October 31st. JPMorgan Chase &amp; Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, September 13th. Finally, Redburn Atlantic upgraded Eli Lilly and Company to a &#34;hold&#34; rating in a research report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $1,002.22.</p>
<div class="lb-trans"><p>几家研究公司最近对 LLY 进行了评估。美国银行在 12 月 10 日的研究报告中重申了对礼来公司的 “买入” 评级，并给出了$997.00 的目标价格。Truist Financial 在 10 月 10 日的报告中将礼来公司的目标价格从$1,000.00 上调至$1,033.00，并给予该公司 “买入” 评级。巴克莱在 10 月 31 日的研究报告中将礼来公司的目标价格从$1,025.00 下调至$975.00，并对该公司设定了 “增持” 评级。摩根大通在 9 月 13 日的报告中将礼来公司的目标价格从$1,050.00 上调至$1,100.00，并给予该股票 “增持” 评级。最后，Redburn Atlantic 在 11 月 4 日的研究报告中将礼来公司升级为 “持有” 评级。四位投资分析师对该股票给予了持有评级，十八位分析师则给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为$1,002.22。</p>
</div><p><strong>Check Out Our Latest Stock Report on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LLY 股票报告</strong></p>
</div><h2>Eli Lilly and Company Stock Up 0.2 %</h2>
<div class="lb-trans"><h2>礼来公司股票上涨 0.2%</h2>
</div><ul>
<li>3 Big-Name Stocks Just Announced Big-Time Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>三只大牌股票刚刚宣布了大幅分红增加</li>
</ul>
</div><p>The stock has a market cap of $734.16 billion, a price-to-earnings ratio of 83.61, a price-to-earnings-growth ratio of 2.99 and a beta of 0.41. The firm's fifty day moving average price is $798.30 and its two-hundred day moving average price is $865.06. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.</p>
<div class="lb-trans"><p>该股市值为 7341.6 亿美元，市盈率为 83.61，市盈增长比率为 2.99，贝塔值为 0.41。该公司的 50 日移动平均价格为$798.30，200 日移动平均价格为$865.06。公司的债务与股本比率为 2.03，流动比率为 1.27，速动比率为 0.97。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm's quarterly revenue was up 20.4% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. Sell-side analysts forecast that Eli Lilly and Company will post 13.18 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日发布了季度财报。该公司报告每股收益为$1.18，低于分析师一致预期的$1.52，差额为 ($0.34)。该公司季度收入为 114.4 亿美元，而分析师预期为 120.9 亿美元。礼来公司的股本回报率为 71.08%，净利润率为 20.48%。该公司的季度收入较去年同期增长了 20.4%。去年同期，该公司每股收益为$0.10。卖方分析师预测，礼来公司在当前财政年度的每股收益将达到$13.18。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加分红</h2>
</div><ul>
<li>Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德：GLP-1 销售的新动力即将到来</li>
</ul>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a yield of 0.78%. Eli Lilly and Company's dividend payout ratio is presently 64.86%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 3 月 10 日支付。2 月 14 日的股东将获得每股$1.50 的分红。这比礼来公司之前的季度分红$1.30 有所增加。除息日为 2 月 14 日。这代表着每年$6.00 的分红和 0.78% 的收益率。礼来公司的分红支付比率目前为 64.86%。</p>
</div><p>Eli Lilly and Company declared that its Board of Directors has initiated a share repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.</p>
<div class="lb-trans"><p>礼来公司宣布其董事会已于 12 月 9 日启动了一项股票回购计划，允许公司回购 150 亿美元的股票。该回购授权允许公司通过公开市场购买最多 2% 的股票。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
</div><h2>Insider Transactions at Eli Lilly and Company</h2>
<div class="lb-trans"><h2>礼来公司的内部交易</h2>
</div><p>In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他礼来公司的新闻中，首席会计官 Donald A. Zakrowski 在 11 月 8 日的交易中出售了 900 股礼来公司的股票。该股票以平均价格$803.38 出售，总交易额为$723,042.00。交易完成后，首席会计官现在持有该公司 5,480 股股票，价值约$4,402,522.40。此次交易使其持股减少了 14.11%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站访问。目前，内部人士持有该股票的 0.13%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of LLY. International Assets Investment Management LLC grew its stake in shares of Eli Lilly and Company by 87,091.7% in the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock worth $11,041,631,000 after acquiring an additional 12,448,888 shares in the last quarter. Pathway Financial Advisers LLC increased its stake in Eli Lilly and Company by 92,759.9% in the 3rd quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company's stock valued at $905,774,000 after buying an additional 1,021,287 shares during the last quarter. Wulff Hansen &amp; CO. lifted its position in shares of Eli Lilly and Company by 90,438.0% during the 2nd quarter. Wulff Hansen &amp; CO. now owns 937,068 shares of the company's stock worth $848,403,000 after buying an additional 936,033 shares in the last quarter. Integrated Investment Consultants LLC boosted its stake in shares of Eli Lilly and Company by 37,140.7% in the 3rd quarter. Integrated Investment Consultants LLC now owns 694,167 shares of the company's stock worth $614,990,000 after buying an additional 692,303 shares during the last quarter. Finally, Comerica Bank grew its holdings in shares of Eli Lilly and Company by 71.6% in the second quarter. Comerica Bank now owns 1,512,983 shares of the company's stock valued at $1,369,825,000 after acquiring an additional 631,312 shares in the last quarter. Institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些大型投资者调整了他们在礼来公司的持股。国际资产投资管理公司在第三季度将其在礼来公司的股份增加了 87,091.7%。国际资产投资管理公司现在拥有 12,463,182 股该公司的股票，价值 11,041,631,000 美元，此前在上个季度又增持了 12,448,888 股。Pathway Financial Advisers LLC 在第三季度将其在礼来公司的股份增加了 92,759.9%。Pathway Financial Advisers LLC 现在拥有 1,022,388 股该公司的股票，价值 905,774,000 美元，此前在上个季度又增持了 1,021,287 股。Wulff Hansen &amp; CO.在第二季度将其在礼来公司的股份增加了 90,438.0%。Wulff Hansen &amp; CO.现在拥有 937,068 股该公司的股票，价值 848,403,000 美元，此前在上个季度又增持了 936,033 股。Integrated Investment Consultants LLC 在第三季度将其在礼来公司的股份增加了 37,140.7%。Integrated Investment Consultants LLC 现在拥有 694,167 股该公司的股票，价值 614,990,000 美元，此前在上个季度又增持了 692,303 股。最后，Comerica Bank 在第二季度将其在礼来公司的持股增加了 71.6%。Comerica Bank 现在拥有 1,512,983 股该公司的股票，价值 1,369,825,000 美元，此前在上个季度又增持了 631,312 股。机构投资者持有该公司 82.53% 的股份。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>What is MarketRank™? How to Use it</li>
<li>3 Legacy Tech Companies Reemerging as AI Leaders</li>
<li>What is a support level?</li>
<li>Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比礼来公司更好的股票</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>3 家传统科技公司重新崛起为 AI 领导者</li>
<li>什么是支撑位？</li>
<li>分析师最喜欢的网络安全股票：3 个顶级推荐</li>
<li>3 只提供优厚股息收益的天然气股票</li>
<li>分析师看好：3 家科技巨头的目标价被上调</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><p>→ We recommended Palantir in 2021, now we’re recommending this... (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 我们在 2021 年推荐了 Palantir，现在我们推荐这个...（来自 Behind the Markets）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTExNQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=11115&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Eli Lilly and Company right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

礼来公司（NYSE:LLY）股价上涨 1% - 现在是买入的好时机吗？